Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4][5]. Company Overview - Organon & Co. develops health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon concealed material information about its capital allocation priorities, particularly regarding the future of its quarterly dividend payout [4]. - It is alleged that Organon's reports on dividend payouts being a "number one priority" were misleading, as they were countered by a new debt reduction strategy that resulted in a more than 70% decrease in the quarterly dividend [4]. - Following the acquisition of Dermavant Sciences Ltd., Organon reportedly prioritized debt reduction over dividend payouts [4]. Financial Impact - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 to $0.02, which led to a stock price decline of over 27% [5].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged securities fraud and unlawful business practices, with a deadline for investors to join the lawsuit by July 22, 2025 [2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Organon and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased or acquired Organon securities during the Class Period are advised to contact Pomerantz LLP to potentially become Lead Plaintiff [2]. Group 2: Financial Performance - On May 1, 2025, Organon reported a significant reduction in its dividend payout from $0.28 to $0.02, indicating a shift in capital allocation priorities to focus on deleveraging [4]. - Following the announcement of the dividend cut, Organon's stock price dropped by $3.48 per share, or 26.91%, closing at $9.45 per share on the same day [4].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's dividend policy following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, specifically titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health and has historically provided a healthy dividend to its shareholders [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased the company's debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, which it claimed was its "1 capital allocation priority," but later shifted its focus to debt reduction, resulting in a significant cut to its dividend [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, leading to a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4]. Company Overview - Organon & Co. develops health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon concealed material information about its capital allocation priorities, particularly regarding the future of its quarterly dividend payout [4]. - It is alleged that Organon's reports on dividend payouts being a "number one priority" were misleading, as they were offset by a newly implemented debt reduction strategy, resulting in a more than 70% decrease in the quarterly dividend [4]. - The lawsuit also states that Organon intended to prioritize debt reduction following its acquisition of Dermavant Sciences Ltd [4]. Financial Impact - On May 1, 2025, Organon reported first quarter 2025 financial results, announcing a reduction in its dividend payout from $0.28 to $0.02, which led to a stock price decline of over 27% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about dividend policies following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health and has historically provided a healthy dividend to its shareholders [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, which was stated as its "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant dividend cut [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

Core Viewpoint - Organon & Co. is facing a securities class action lawsuit for failing to disclose material information during the class period, which has led to significant financial repercussions for the company and its investors [3][4]. Group 1: Lawsuit Details - Investors have until July 22, 2025, to file lead plaintiff applications in the lawsuit against Organon & Co. for securities purchased between October 31, 2024, and April 30, 2025 [1]. - The lawsuit is pending in the United States District Court for the District of New Jersey, under the case name Hauser V. Organon & Co., et al., No. 25-cv-05322 [5]. Group 2: Financial Impact - On March 10, 2025, Organon announced a drastic reduction in its dividend payout from $0.28 to $0.02, which contradicted previous assurances to investors regarding the importance of maintaining the dividend [4]. - Following the announcement of the dividend cut, Organon's share price plummeted over 27%, dropping from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025 [4]. Group 3: ClaimsFiler Information - ClaimsFiler is a free shareholder information service that assists investors in recovering funds from securities class action settlements [6]. - The service allows investors to register for free, upload portfolio data, and submit inquiries for case evaluations [6].

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly providing misleading statements regarding its capital allocation and dividend strategy, particularly following its acquisition of Dermavant [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Organon securities between October 31, 2024, and April 30, 2025 [1]. - Investors have until July 22, 2025, to apply to be appointed as lead plaintiff in the lawsuit [1]. Group 2: Allegations - Defendants allegedly made overwhelmingly positive statements while concealing material adverse facts about Organon's priorities, especially regarding capital allocation and debt reduction [3]. - The lawsuit highlights a significant reduction in the regular quarterly dividend by 70% due to the prioritization of debt reduction following the acquisition of Dermavant [3]. Group 3: Stock Price Impact - Following the news of the lawsuit, Organon's stock price dropped from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [4].

Group 1 - The class action was filed on behalf of investors who purchased Organon & Co. securities between October 31, 2024, and April 30, 2025 [1] - Organon is a global healthcare company focused on improving women's health throughout their lives [1] - The allegations include misleading statements regarding Organon's capital allocation strategy, particularly its prioritization of regular quarterly dividends [2] Group 2 - The complaint claims that while promoting a strong capital allocation strategy, Organon concealed the high priority of its debt reduction strategy following the acquisition of Dermavant, leading to a 70% decrease in the regular quarterly dividend [3] - The truth was revealed on May 1, 2025, when Organon announced a significant reduction in its dividend payout from $0.28 to $0.02, resulting in a stock price decline of over 27% [4] Group 3 - Shareholders interested in participating in the class action or serving as lead plaintiff are encouraged to contact the firm [5] - Robbins LLP operates on a contingency fee basis, meaning shareholders pay no fees or expenses [6]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Organon & Co. securities for the period between October 31, 2024, and April 30, 2025, alleging misleading statements regarding the company's capital allocation and dividend strategy [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Organon provided positive statements to investors while concealing material adverse facts, particularly regarding its debt reduction strategy after acquiring Dermavant, which led to a 70% decrease in the regular quarterly dividend [5]. - Investors who purchased Organon securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must file a motion with the court by July 22, 2025, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including over $438 million for investors in 2019 [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for allegedly misrepresenting its capital allocation priorities and significantly reducing its quarterly dividend [1][7]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the District of New Jersey [1]. - Investors who acquired Organon shares during the class period (October 31, 2024 – April 30, 2025) are encouraged to contact the law firm before the lead plaintiff motion deadline on July 22, 2025 [1][3][7]. Group 2: Allegations Against Organon - Organon is accused of concealing material information regarding its capital allocation priorities, particularly in relation to its quarterly dividend [7]. - The company publicly emphasized dividends as a top priority while internally shifting focus towards debt reduction [7]. - Following the acquisition of Dermavant Sciences Ltd., Organon drastically reduced its quarterly dividend by over 90% [7]. Group 3: Law Firm Background - Wolf Haldenstein Adler Freeman & Herz LLP has over 125 years of legal expertise in securities litigation and aims to protect the rights of investors [4].